SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Sarah K. Browne, Anticytokine Autoantibody–Associated Immunodeficiency*, Annual Review of Immunology, 2014, 32, 1, 635

    CrossRef

  2. 2
    S. Lambrecht, N. Juchtmans, D. Elewaut, Heat-shock proteins in stromal joint tissues: innocent bystanders or disease-initiating proteins?, Rheumatology, 2014, 53, 2, 223

    CrossRef

  3. 3
    Pauline A. van Schouwenburg, Theo Rispens, Gerrit Jan Wolbink, Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis, Nature Reviews Rheumatology, 2013, 9, 3, 164

    CrossRef

  4. 4
    Tomokazu Kawaoka, Nobuhiko Hiraga, Shoichi Takahashi, Shintaro Takaki, Masataka Tsuge, Yuko Nagaoki, Yoshimasa Hashimoto, Yoshio Katamura, Daiki Miki, Akira Hiramatsu, Koji Waki, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Hirotaka Tashiro, Hideki Ohdan, Kazuaki Chayama, Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon a-2b to a-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report, Intervirology, 2012, 55, 4, 122

    CrossRef

  5. 5
    F. Matsuda, Y. Torii, H. Enomoto, C. Kuga, N. Aizawa, Y. Iwata, M. Saito, H. Imanishi, S. Shimomura, H. Nakamura, H. Tanaka, H. Iijima, H. Tsutsui, Y. Tanaka, S. Nishiguchi, Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C, Journal of Viral Hepatitis, 2012, 19, 10
  6. 6
    Xiao-Yan Cai, Jeff Thomas, Constance Cullen, Dominique Gouty, Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development, Bioanalysis, 2012, 4, 17, 2169

    CrossRef

  7. 7
    Patrick B. Deegan, Fabry disease, enzyme replacement therapy and the significance of antibody responses, Journal of Inherited Metabolic Disease, 2012, 35, 2, 227

    CrossRef

  8. 8
    O. P. Kulkarni, M. Ryu, C. Kantner, M. Sardy, D. Naylor, D. Lambert, R. Brown, H.-J. Anders, Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice, Nephrology Dialysis Transplantation, 2012, 27, 4, 1358

    CrossRef

  9. 9
    Essam H. Ibrahim, Anti-IFN autoantibodies are present in healthy Egyptian blood donors at low titer, Cellular Immunology, 2011, 271, 2, 365

    CrossRef

  10. 10
    David R. Strayer, William A. Carter, Recombinant and Natural Human Interferons: Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies, Journal of Interferon & Cytokine Research, 2011, 111201131520004

    CrossRef

  11. 11
    Sarah K Browne, Steven M Holland, Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms, The Lancet Infectious Diseases, 2010, 10, 12, 875

    CrossRef

  12. 12
    Philippe Halfon, Sophie Pérusat, Marc Bourlière, Jean-Pierre Bronowicki, Pascale Trimoulet, Yves Benhamou, Vincent Leroy, Patrick Marcellin, Juliette Foucher, Guillaume Penaranda, Geneviève Chêne, Patrice Couzigou, Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy*), Journal of Medical Virology, 2010, 82, 12
  13. 13
    Dongsheng Xu, Luwen Zhang, Viral transformation for production of personalized type I interferons, Biotechnology Journal, 2010, 5, 6
  14. 14
    Meyler's Side Effects of Drugs in Cancer and Immunology, 2010,

    CrossRef

  15. You have free access to this content15
    B. De Felipe, M. Leal, N. Soriano-Sarabia, A. Gutiérrez, L. López-Cortés, S. Molina-Pinelo, A. Vallejo, HCV RNA in peripheral blood cell subsets in HCV–HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse, Journal of Viral Hepatitis, 2009, 16, 1
  16. 16
    Philippe M Campeau, Moutih Rafei, Moïra François, Elena Birman, Kathy-Ann Forner, Jacques Galipeau, Mesenchymal Stromal Cells Engineered to Express Erythropoietin Induce Anti-erythropoietin Antibodies and Anemia in Allorecipients, Molecular Therapy, 2009, 17, 2, 369

    CrossRef

  17. 17
    Gopi Shankar, Charles Pendley, Kathryn E Stein, A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs, Nature Biotechnology, 2007, 25, 5, 555

    CrossRef

  18. 18
    Veronique Nussenblatt, Mary McLaughlin, Catherine A. Rehm, Richard A. Lempicki, Terry Brann, Jun Yang, Michael Proschan, Helene C. Highbarger, Robin L. Dewar, Tom Imamichi, Chad Koratich, Avidan U. Neumann, Henry Masur, Michael A. Polis, Shyam Kottilil, Immunodeficiency and Intrinsic IFN Resistance Are Associated with Viral Breakthrough to HCV Therapy in HIV-Coinfected Patients, AIDS Research and Human Retroviruses, 2007, 23, 11, 1354

    CrossRef

  19. 19
    Basant Sharma, Immunogenicity of therapeutic proteins. Part 1: Impact of product handling, Biotechnology Advances, 2007, 25, 3, 310

    CrossRef

  20. 20
    Belen Ramos, Julie Sheldon, Andres Ruiz-Sancho, Carlos Toro, Pilar Ríos, Vincent Soriano, Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients, AIDS, 2007, 21, 5, 652

    CrossRef

  21. You have free access to this content21
    Carl Jorns, Dirk Holzinger, Robert Thimme, Hans Christian Spangenberg, Manfred Weidmann, Jens Rasenack, Hubert Erich Blum, Otto Haller, Georg Kochs, Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-α, Journal of Medical Virology, 2006, 78, 1
  22. 22
    Gopi Shankar, Elizabeth Shores, Carrie Wagner, Anthony Mire-Sluis, Scientific and regulatory considerations on the immunogenicity of biologics, Trends in Biotechnology, 2006, 24, 6, 274

    CrossRef

  23. 23
    Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 2006,

    CrossRef

  24. 24
    H.-P. Hartung, F. Munschauer, H. Schellekens, Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference, European Journal of Neurology, 2005, 12, 8
  25. 25
    Simon F. Peek, Michael D. Bonds, Patrick Schaele, Sarah Weber, Kristin Friedrichs, Ronald D. Schultz, Evaluation of antiviral activity and toxicity of recombinant human interferon alfa-2a in calves persistently infected with type 1 bovine viral diarrhea virus, American Journal of Veterinary Research, 2004, 65, 6, 865

    CrossRef

  26. 26
    Huub Schellekens, Immunogenicity of therapeutic proteins: Clinical implications and future prospects, Clinical Therapeutics, 2002, 24, 11, 1720

    CrossRef

  27. 27
    Carolina Scagnolari, Francesca Bellomi, Ombretta Turriziani, Francesca Bagnato, Valentina Tomassini, Vito Lavolpe, Marilena Ruggieri, Fabrizio Bruschi, Giuseppe Meucci, Giordano Dicuonzo, Guido Antonelli, Neutralizing and Binding Antibodies to IFN-β: Relative Frequency in Relapsing-Remitting Multiple Sclerosis Patients Treated with Different IFN-βPreparations, Journal of Interferon & Cytokine Research, 2002, 22, 2, 207

    CrossRef

  28. 28
    Ke-Qin Hu, John M. Vierling, Allan G. Redeker, Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection, Journal of Viral Hepatitis, 2001, 8, 1, 1

    CrossRef

  29. 29
    Ke-Qin Hu, John M. Vierling, Allan G. Redeker, Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection, Journal of Viral Hepatitis, 2001, 8, 1
  30. 30
    E. Jenny Heathcote, Stephen James, Kevin D. Mullen, S. C. Hauser, H. Rosenblate, Donald G. Albert, Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon, Hepatology, 1999, 30, 2
  31. 31
    G. ANTONELLI, F. BAGNATO, C. POZZILLI, E. SIMEONI, S. BASTIANELLI, M. CURRENTI, F. DE PISA, C. FIESCHI, C. GASPERINI, M. SALVETTI, F. DIANZANI, Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1a, Journal of Interferon & Cytokine Research, 1998, 18, 5, 345

    CrossRef

  32. 32
    Leslie C. Grammer, IMMUNOLOGIC REACTION TO INSULIN AND OTHER PROTEINS, Immunology and Allergy Clinics of North America, 1998, 18, 4, 809

    CrossRef

  33. 33
    Peter H. Meide, Huub Schellekens, Anti-cytokine autoantibodies: Epiphenomenon or critical modulators of cytokine action, Biotherapy, 1997, 10, 1, 39

    CrossRef

  34. 34
    G. Antonelli, E. Simeoni, M. Currenti, F. Pisa, V. Colizzi, M. Pistello, F. Dianzani, Interferon antibodies in patients with infectious diseases, Biotherapy, 1997, 10, 1, 7

    CrossRef

  35. 35
    Thierry Vial, Jacques Descotes, 1997,

    CrossRef

  36. 36
    Susan Kirshner, Immunogenicity of Therapeutic Proteins: A Regulatory Perspective,
  37. 37
    Andrew Erdman, James Nickas, Benton Brown, Safety of Biotherapeutics,